Biotricity Completes Development of its ECG Patch Platform
Company Prepares for FDA Filing of New Device
REDWOOD CITY, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has completed development of its ECG patch platform. An extension of the company's award-winning Bioflux(R) device, Biopatch is ideal for patients with less complicated cardiac conditions. The patch leverages the advanced diagnostic capabilities of Bioflux(R) in a miniaturized form factor with 3 standard electrodes but no lead wires. It provides wireless communication to enable real-time monitoring for patients who are either at risk for, or diagnosed with, certain cardiac issues. The patch is currently undergoing internal clinical testing; once testing is complete the company will file a 510(k) clearance application with the US FDA.
"With development of the patch completed, we've achieved the most significant milestone in bringing our product to the market," said Mr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "We took special care to develop our patch platform to ensure that our solution overcomes all of the limitations that other ECG patches in the market currently have. It's with great pride that I can affirm that we have done exactly that. Biopatch will allow us to widen our commercial reach, offering patients a more convenient monitoring solution without compromising diagnostic quality."
The company's flagship product Bioflux(R) already offers advanced diagnostics for ambulatory patients and patients who are at high risk for adverse heart effects. A miniaturized application of the Bioflux(R) technology, Biopatch extends the same advanced diagnostics while offering patients a more convenient, less cumbersome monitoring solution to encourage greater user compliance.
Biopatch Key Features
-- 3-channel solution, industry-recommended for best diagnostic yield
-- Compact and comfortable with high usability
-- A 3-in-1 solution offering Event, Holter, and Extended Holter monitoring;
future extension will allow for mobile cardiac telemetry (MCT) monitoring
-- Wireless communication to enable real-time monitoring
-- Ensures advanced conduction & flexibility for all skin types, designed to
use standard electrodes
-- Automated wireless uploading addresses diagnostic and report turn-around
issues that current patches face
-- Rechargeable to address battery limitations that other patches in the
market currently face
Continuous ECG monitoring patches that patients wear at home have been found to significantly increase detection of atrial fibrillation (AF), according to an industry-funded study in JAMA. AF can lead to serious heart-related complications, including stroke and heart failure. Small, comfortable, and effective, Biopatch will ensure patients with AF and other cardiac issues receive early diagnosis and preemptive care from their physicians
